Nordea Investment Management AB Buys 30,764 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Nordea Investment Management AB boosted its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 13.0% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 266,588 shares of the biopharmaceutical company's stock after buying an additional 30,764 shares during the period. Nordea Investment Management AB owned approximately 0.47% of Agios Pharmaceuticals worth $7,824,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Quest Partners LLC purchased a new stake in shares of Agios Pharmaceuticals during the fourth quarter valued at approximately $41,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Agios Pharmaceuticals by 352.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,469 shares of the biopharmaceutical company's stock valued at $144,000 after purchasing an additional 5,040 shares during the period. NEOS Investment Management LLC purchased a new stake in shares of Agios Pharmaceuticals during the fourth quarter valued at approximately $210,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Agios Pharmaceuticals by 9.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,444 shares of the biopharmaceutical company's stock valued at $255,000 after purchasing an additional 942 shares during the period. Finally, Handelsbanken Fonder AB raised its stake in shares of Agios Pharmaceuticals by 31.8% during the fourth quarter. Handelsbanken Fonder AB now owns 12,023 shares of the biopharmaceutical company's stock valued at $268,000 after purchasing an additional 2,900 shares during the period.

Agios Pharmaceuticals Stock Performance

Shares of AGIO traded up $1.51 during midday trading on Tuesday, hitting $42.70. 685,655 shares of the stock traded hands, compared to its average volume of 814,976. Agios Pharmaceuticals, Inc. has a 1-year low of $19.80 and a 1-year high of $49.06. The firm has a market capitalization of $2.42 billion, a PE ratio of -6.76 and a beta of 0.79. The business's 50 day moving average price is $39.73 and its two-hundred day moving average price is $31.64.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) EPS for the quarter, topping the consensus estimate of ($1.65) by $0.20. Agios Pharmaceuticals had a negative net margin of 1,199.26% and a negative return on equity of 41.41%. The firm had revenue of $8.19 million for the quarter, compared to analysts' expectations of $8.37 million. During the same period in the previous year, the business earned ($1.47) earnings per share. Agios Pharmaceuticals's revenue for the quarter was up 46.0% compared to the same quarter last year. As a group, equities research analysts forecast that Agios Pharmaceuticals, Inc. will post -2.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Royal Bank of Canada lifted their price target on shares of Agios Pharmaceuticals from $44.00 to $53.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 4th. JPMorgan Chase & Co. restated a "neutral" rating and issued a $46.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Agios Pharmaceuticals in a report on Monday, June 17th. The Goldman Sachs Group lifted their price objective on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a "neutral" rating in a report on Tuesday, June 4th. Finally, StockNews.com downgraded shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Wednesday, July 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $50.67.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,791 shares of the business's stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $27.55, for a total value of $214,642.05. Following the sale, the director now directly owns 137,396 shares in the company, valued at $3,785,259.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.93% of the stock is owned by company insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.